Study #2024-0504
COG ACNS1931: A phase 3 study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in combination with Vinblastine for non-NF1, non-TSC patients with recurrent or progressive low-grade gliomas (LGGs) lacking BRAFV600E or IDH1 mutations
MD Anderson Study Status
Enrolling
Treatment Agent
Selumetinib Sulfate, Vinblastine Sulfate
Description
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth by stopping cell division and may kill cancer cells. Giving selumetinib in combination with vinblastine may work better than selumetinib alone in treating recurrent or progressive low-grade glioma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma, Refractory Low Grade Glioma, Refractory WHO Grade 1 Glioma
Study phase:
Phase III
Physician name:
Najat Daw Bitar
Department:
Pediatrics
For general questions about clinical trials:
1-866-599-0508
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.